Cambrian BioPharma, a US-based, multi-asset longevity biotech company, announced on Wednesday that it has named Ruth Thieroff-Ekerdt, MD as its new executive vice president of Clinical Development effective 7 September 2022.

Dr Thieroff-Ekerdt joins Cambrian with more than 30 years of global experience in pharmaceutical and biotech organisations. She has held the position of scientific advisor at Organon and acting chief medical officer at Forendo, an entity acquired by Organon. Dr Thieroff-Ekerdt has also served as chief medical officer at Sojournix, Aptalis, Strongbridge and Kaleido and in R&D positions of increasing responsibility at Bayer.

In the new role, Dr Thieroff-Ekerdt will be responsible for a wide range of development activities including the continuation and creation of clinical development and strategy. She will handle all aspects of clinical development for the company, including indication and regulatory strategy; design and conduct of clinical trials; setting up KOL networks; the selection of clinical trial sites; training of physicians and management of CROs; and the oversight, analysis, and interpretation of clinical data and management of regulatory and clinical operations activities.